苄达赖氨酸的一般药理学研究。 - Suppr | 超能文献

General pharmacological investigations on bendazac lysine.

作者信息

Cioli V, Corradino C, Mazzanti G, Silvestrini B

出版信息

Farmaco Prat. 1984 Dec;39(12):438-54.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

General pharmacological investigations on bendazac lysine.苄达赖氨酸的一般药理学研究。

Farmaco Prat. 1984 Dec;39(12):438-54.

2

Pharmacological investigations on lonidamine.氯尼达明的药理学研究。

Arzneimittelforschung. 1984;34(4):455-60.

3

Experimental studies on the interactions between corticosteroids and bendazac after topical application to the skin.皮质类固醇与苄达酸局部应用于皮肤后相互作用的实验研究。

Boll Chim Farm. 1975 Jul;114(7):401-7.

4

Photosensitized haemolysis of human erythrocytes is reduced by bendazac.苄达酸可减少人红细胞的光敏性溶血。

Drugs Exp Clin Res. 1989;15(5):219-22.

5

[Pharmacological studies of N-benzoyl-N'-phenyl-2,6-diaminobenzoic acid (F1). 3. Interaction with proteins].N-苯甲酰基-N'-苯基-2,6-二氨基苯甲酸（F1）的药理研究。3. 与蛋白质的相互作用

Nihon Yakurigaku Zasshi. 1973 Nov;69(6):918-29.

6

[Pharmacological analysis of 5,6-dimethoxy indazole derivatives].5,6-二甲氧基吲唑衍生物的药理学分析

Acta Pharm Hung. 1973 Jul;43(3):147-51.

7

Pharmacological and toxicological studies with 1-benzyl-3-(2,3-dihydroxypropoxy)indazole.1-苄基-3-(2,3-二羟基丙氧基)吲唑的药理和毒理学研究

Arzneimittelforschung. 1976;26(7):1393-7.

8

In vivo influence of bendazac, (AF-983), a non-steroideal anti-inflammatory drug, on the Krebs cycle in rabbit liver.非甾体抗炎药苄达酸（AF - 983）对兔肝脏中三羧酸循环的体内影响。

Boll Chim Farm. 1986 Nov;125(11):379-83.

9

Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts.

Drugs. 1990 Apr;39(4):575-96. doi: 10.2165/00003495-199039040-00007.

10

Basic data supporting the use of the l-lysine salt of bendazac in cataract.

Int J Tissue React. 1983;5(2):217-25.

引用本文的文献

1

Animal models for the study of atypical anti-inflammatory agents.用于研究非典型抗炎药的动物模型。

Agents Actions. 1986 Jan;17(3-4):329-37. doi: 10.1007/BF01982638.

2

Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts.

Drugs. 1990 Apr;39(4):575-96. doi: 10.2165/00003495-199039040-00007.